McKenna et al15 developed a specific measure of HRQoL for PH: the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). CAMPHOR was developed following in-depth qualitative unstructured recorded interviews with PH patients from a single PH center in the United Kingdom. The emphasis of the interview was for patients to convey their PH experience, in particular, descriptions of the physical and psychological impact of PH on their lives. The CAMPHOR questionnaire consists of three scales: (1) a 25-item overall symptoms scale with three subscales (energy, breathlessness, mood), (2) a 15-item functioning scale, and (3) a 25-item QoL scale that indicates how well the patients meet their own needs. In the final validation postal survey of 91 men and women, the mean age was 52.6 years, 35.6% were living alone, 36% had idiopathic PAH, 33% had CTEPH, 23% had congenital heart disease, and 6.6% had connective tissue diseases.19 CAMPHOR could be helpful for PH patients, caregivers, and the scientific and pharmaceutical communities. It has recently been validated in the United States, where a single-center study confirmed a good test-retest reliability and internal consistency; CAMPHOR scales correlated with the Medical Outcomes Study 36-item short form (SF-36) and 6-MW test.22 It has not been validated based on consideration of treatment and health insurance availability, and it was developed in a diverse PH cohort. Whether the same QoL measure should be used in patients with CTEPH, idiopathic PAH, and PAH with associated conditions (especially connective tissue diseases, HIV, congenital heart disease, and portal hypertension) remains to be determined.